Effects of the SGLT2 inhibitor empagliflozin in patients with euvolemic and hypervolemic hyponatremia - a multicentric randomized double-blind placebo-controlled trial - the EMPOWER Study

Effects of the SGLT2 inhibitor empagliflozin in patients with euvolemic and hypervolemic hyponatremia – a multicentric randomized double-blind placebo-controlled trial - the EMPOWER Study

SNF Schweizerischer Nationalfonds, 10.2022-09.2026 (48)

PI : Christ-Crain, Mirjam.